Denali Therapeutics Inc.
DNL593
GRN-related frontotemporal dementia (FTD-GRN)
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for DNL593 in GRN-related frontotemporal dementia (FTD-GRN) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Enrollment in the study is complete with a total of 40 participants with FTD-GRN, and results are expected by the end of 2026.”